Oncology - Physician's Weekly - Page 2

Oncology

Pembrolizumab and carboplatin plus docetaxel treatment regimens may provide options for patients with triple-negative breast cancer who are ineligible for anthracycline-based regimens

Nov 28, 2023

1. Overall pathologic complete response to treatment of triple-negative breast cancer with a...

Nov 21, 2023

1. Progression-free survival was not reached in the selpercatinib group and was 16.8 months in the...

Nov 19, 2023

1. For patients with unfavorable nonmetastatic prostate cancer aged above 70 years, PSA levels...

Nov 14, 2023

Bookmark1. A greater percentage of patients who received concurrent stereotactic radiation therapy...

Nov 14, 2023

Bookmark1. Progression-free survival was 6.3 months for the amivantamab–chemotherapy group, 8.3...